- Home
- ALLO vs NLOP Comparison
ALLO vs NLOP Comparison
Compare ALLO & NLOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLO
- NLOP
- Stock Information
- Founded
- ALLO 2017
- NLOP 2022
- Country
- ALLO United States
- NLOP United States
- Employees
- ALLO N/A
- NLOP N/A
- Industry
- ALLO Biotechnology: Biological Products (No Diagnostic Substances)
- NLOP
- Sector
- ALLO Health Care
- NLOP
- Exchange
- ALLO Nasdaq
- NLOP Nasdaq
- Market Cap
- ALLO 438.2M
- NLOP 470.6M
- IPO Year
- ALLO 2018
- NLOP N/A
- Fundamental
- Price
- ALLO $1.82
- NLOP $31.71
- Analyst Decision
- ALLO Strong Buy
- NLOP Strong Buy
- Analyst Count
- ALLO 10
- NLOP 1
- Target Price
- ALLO $10.06
- NLOP $46.00
- AVG Volume (30 Days)
- ALLO 3.1M
- NLOP 177.8K
- Earning Date
- ALLO 03-13-2025
- NLOP 01-01-0001
- Dividend Yield
- ALLO N/A
- NLOP 1.07%
- EPS Growth
- ALLO N/A
- NLOP N/A
- EPS
- ALLO N/A
- NLOP N/A
- Revenue
- ALLO $43,000.00
- NLOP $160,911,000.00
- Revenue This Year
- ALLO N/A
- NLOP N/A
- Revenue Next Year
- ALLO N/A
- NLOP N/A
- P/E Ratio
- ALLO N/A
- NLOP N/A
- Revenue Growth
- ALLO 26.47
- NLOP N/A
- 52 Week Low
- ALLO $1.78
- NLOP $22.16
- 52 Week High
- ALLO $5.78
- NLOP $33.06
- Technical
- Relative Strength Index (RSI)
- ALLO 36.69
- NLOP 54.22
- Support Level
- ALLO $2.11
- NLOP $28.54
- Resistance Level
- ALLO $2.10
- NLOP $32.88
- Average True Range (ATR)
- ALLO 0.17
- NLOP 1.09
- MACD
- ALLO -0.02
- NLOP 0.21
- Stochastic Oscillator
- ALLO 5.69
- NLOP 73.04
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.
About NLOP Net Lease Office Properties of Beneficial Interest
Net Lease Office Properties is a real estate investment trust. Through its subsidiaries it owns, operates, and finances office buildings. Its properties are primarily leased to corporate tenants on a single-tenant, net-lease basis. Its portfolio includes approximately 1.5 million square feet of Green-Certified Buildings, 4 LEED-Certified Buildings, and 1 BREEAM-Certified Building.